UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~March~~April 2026

Commission File Number: 001-39173

NovaBridge Biosciences

2440 Research Boulevard, Suite 400

Rockville, MD 20850

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒                Form 40-F ☐

On ~~March~~April 167, 2026, NovaBridge Biosciences issued a press release, and a ~~copy~~corporate presentation, copies of which isare furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively.

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release - NovaBridge ~~Announces~~Reports ~~Productive~~Full ~~FDA~~Year ~~Type~~2025 BFinancial ~~Meeting~~Results onand ~~Potential~~Provides ~~Accelerated~~Business ~~Approval Pathway for Givastomig in Gastric Cancer~~Update
99.2	Corporate Presentation - April 7, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


NovaBridge Biosciences

By	:	/s/ Xi-Yong Fu
Name	:	Xi-Yong (Sean) Fu
Title	:	Chief Executive Officer

Date: ~~March~~April 167, 2026

Filing Compare · NovaBridge Biosciences